Drug news
FDA will review cabozantinib (Exelixis Inc) as a treatment for Thyroid Ccancer on 29 November 2012
Exelixis, Inc.announced that the FDA has accepted for filing the New Drug Application (NDA) for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary Thyroid Cancer (MTC). The FDA also granted priority review designation to the NDA for cabozantinib. The Prescription Drug User Fee Act (PDUFA) action date is November 29, 2012.